Evotec SE to Announce Results for Financial Year 2024 on 17 April 2025
Evotec SE (NASDAQ: EVO) has scheduled the announcement of its financial year 2024 results for Thursday, April 17, 2025. The company will host a conference call at 2:00 PM CEST (1:00 PM BST, 8:00 AM ET) to discuss the results and provide updates on their concluded strategic review process.
The presentation will be conducted in English and will be accessible via both webcast and phone conference. Participants joining via phone must pre-register to receive dedicated dial-in details. The company will make an on-demand version of the webcast available on their website following the presentation.
Evotec SE (NASDAQ: EVO) ha programmato l'annuncio dei risultati del anno finanziario 2024 per giovedì 17 aprile 2025. L'azienda ospiterà una conference call alle 14:00 CEST (13:00 BST, 8:00 ET) per discutere i risultati e fornire aggiornamenti sul processo di revisione strategica concluso.
La presentazione sarà condotta in inglese e sarà accessibile sia tramite webcast che tramite conferenza telefonica. I partecipanti che si uniscono tramite telefono devono registrarsi in anticipo per ricevere i dettagli di accesso dedicati. L'azienda renderà disponibile una versione on-demand del webcast sul proprio sito web dopo la presentazione.
Evotec SE (NASDAQ: EVO) ha programado el anuncio de sus resultados del año fiscal 2024 para el jueves 17 de abril de 2025. La empresa llevará a cabo una conferencia telefónica a las 2:00 PM CEST (1:00 PM BST, 8:00 AM ET) para discutir los resultados y proporcionar actualizaciones sobre su proceso de revisión estratégica concluido.
La presentación se realizará en inglés y será accesible tanto por webcast como por conferencia telefónica. Los participantes que se unan por teléfono deben registrarse previamente para recibir los detalles de acceso dedicados. La empresa pondrá a disposición una versión bajo demanda del webcast en su sitio web después de la presentación.
Evotec SE (NASDAQ: EVO)는 2025년 4월 17일 목요일에 2024 회계연도 실적 발표를 예정하고 있습니다. 회사는 오후 2:00 CEST (오후 1:00 BST, 오전 8:00 ET)에 실적을 논의하고 완료된 전략 리뷰 프로세스에 대한 업데이트를 제공하기 위해 컨퍼런스 콜을 개최할 것입니다.
발표는 영어로 진행되며 웹캐스트와 전화 회의 모두에서 접근할 수 있습니다. 전화로 참여하는 참가자는 전용 다이얼인 세부정보를 받기 위해 사전 등록해야 합니다. 발표 후 회사는 웹사이트에서 웹캐스트의 주문형 버전을 제공할 것입니다.
Evotec SE (NASDAQ: EVO) a programmé l'annonce de ses résultats de l'exercice 2024 pour le jeudi 17 avril 2025. L'entreprise organisera une conférence téléphonique à 14h00 CEST (13h00 BST, 8h00 ET) pour discuter des résultats et fournir des mises à jour sur leur processus de révision stratégique conclu.
La présentation sera réalisée en anglais et sera accessible à la fois par webcast et par conférence téléphonique. Les participants rejoignant par téléphone doivent s'inscrire à l'avance pour recevoir les détails d'accès dédiés. L'entreprise mettra à disposition une version à la demande du webcast sur son site web après la présentation.
Evotec SE (NASDAQ: EVO) hat die Bekanntgabe der Finanzergebnisse für das Jahr 2024 für Donnerstag, den 17. April 2025, angesetzt. Das Unternehmen wird um 14:00 Uhr CEST (13:00 Uhr BST, 8:00 Uhr ET) eine Telefonkonferenz abhalten, um die Ergebnisse zu besprechen und Updates zu ihrem abgeschlossenen strategischen Überprüfungsprozess zu geben.
Die Präsentation wird in Englisch durchgeführt und ist sowohl über Webcast als auch über Telefonkonferenz zugänglich. Teilnehmer, die per Telefon teilnehmen, müssen sich im Voraus registrieren, um die speziellen Einwahldaten zu erhalten. Das Unternehmen wird eine On-Demand-Version des Webcasts nach der Präsentation auf seiner Website zur Verfügung stellen.
- None.
- None.
HAMBURG, DE / ACCESS Newswire / April 10, 2025 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) will announce its financial results for 2024 on Thursday, 17 April 2025.
The Company is going to host a conference call to discuss 2024 results as well as to provide an update on the concluded strategic review process. The conference call will be held in English.
Webcast details
Date: Thursday, 17 April 2025
Time: 2.00 pm CEST (1.00 pm BST, 8.00 am ET)
To join the audio webcast and to access the presentation slides, please register via this link.
The on-demand version of the webcast will be available on our website: www.evotec.com.
Conference call details
To join via phone, please pre-register via this link .
You will then receive a confirmation email with dedicated dial-in details such as telephone number, access code and PIN to access the call.
A simultaneous slide presentation for participants dialing in via phone is available under this link .
About Evotec SE
Evotec is a life science company with a unique business model that delivers on its mission to discover and develop highly effective therapeutics and make them available to the patients. The Company's multimodality platform comprises a unique combination of innovative technologies, data and science for the discovery, development, and production of first-in-class and best-in-class pharmaceutical products. Evotec provides high value pipeline co-creating partnerships and solutions to all Top 20 Pharma and over 800 biotechnology companies, academic institutions, as well as other healthcare stakeholders. Evotec has strategic activities in a broad range of currently underserved therapeutic areas, including e.g. neurology, oncology, as well as metabolic and infectious diseases. Within these areas of expertise, Evotec aims to create the world-leading co-owned pipeline for innovative therapeutics and has to-date established a portfolio of more than 100 proprietary and co-owned R&D projects from early discovery to clinical development. Evotec operates globally with more than 4,800 highly qualified people. The Company's sites in Europe and the USA offer highly synergistic technologies and services and operate as complementary clusters of excellence. For additional information please go to www.evotec.com and follow us on X/Twitter @Evotec and LinkedIn .
Forward-looking statements
This announcement contains forward-looking statements concerning future events, including the proposed offering and listing of Evotec's securities. Words such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "might," "plan," "potential," "should," "target," "would" and variations of such words and similar expressions are intended to identify forward-looking statements. Such statements include comments regarding Evotec's expectations for revenues, Group EBITDA and R&D expenses. These forward-looking statements are based on the information available to, and the expectations and assumptions deemed reasonable by Evotec at the time these statements were made. No assurance can be given that such expectations will prove to have been correct. These statements involve known and unknown risks and are based upon a number of assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond the control of Evotec. Evotec expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Evotec's expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.
For further information, please contact:
Investor Relations
Volker Braun
EVP Head of Global Investor Relations & ESG
Volker.Braun@evotec.com
SOURCE: Evotec SE
View the original press release on ACCESS Newswire
FAQ
When will Evotec SE (EVO) release its 2024 financial results?
What time is Evotec's (EVO) 2024 earnings call scheduled for?
Will Evotec (EVO) provide an update on their strategic review process?
How can investors access Evotec's (EVO) 2024 earnings presentation?
